CHICAGO — Ventas Inc. (NYSE: VTR) has appointed Sean Nolan, former chief executive officer of gene therapy company AveXis, as an independent member of its Board of Directors.
“Sean is an incredible addition to our diverse, experienced and independent Board of Directors,” says Debra Cafaro, Ventas chairman and CEO. “With three decades of extensive experience in the biopharmaceutical industry and a proven track record of business accomplishment, Sean will contribute unique and complementary insights to enhance our rapidly expanding research and innovation business and our enterprise growth.”
With Nolan’s addition, the Ventas Board of Directors totals 10 individuals, with nine independent members. Nolan will initially serve on the company’s Audit and Compliance Committee.